Ariana expands operations to USA

06-Jun-2012 - USA

Ariana Pharma announced that it has expanded its global operations by establishing a permanent US office in Cambridge, Massachusetts to service growing demand for its unique and powerful data analytics technology KEM (R).

In conjunction with the opening, Ariana has appointed James M. Shanahan as VP of business development. James was previously a co-founder and is current board member of SynDevRx, Inc., an oncology-focused biotech company and was a co-founder and VP corporate development of JAM Technologies, Inc. James brings 15 years business development and marketing experience to Ariana.

“The US pharma and biotech markets tend to be early technology adopters, and are searching for better data analytics tools to advance personalized medicine using all the new biomarker, genomic, proteomic and metabolomic data now being generated,” said Dr. Mohammad Afshar, president and CEO of Ariana Pharma. “Our KEM technology is the only proven approach that can simultaneously analyze all these variables and pull out patient responder sub-groups, optimize biomarker signatures and remove bias from clinical trials.”

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance